TriGemX Bio agrees $246m SPAC deal to advance elismetrep migraine trials
TriGemX Bio plans a $246 million SPAC transaction to fund Phase 3 elismetrep trials. Clinical results and deal completion will determine its future.
Pharma & Biotech
Pharma & Biotech
Can ME Therapeutics’ CD19 CD22 CAR designs address resistance in B-cell cancers?
ME Therapeutics extends its CD22 nanobody option to February 2027. Examine dual-target CAR development, licensing and clinical challenges.
Medical Devices & Diagnostics
What bioAffinity Technologies’ $4m financing means for CyPath Lung growth
bioAffinity Technologies closes $4 million financing as CyPath Lung sales grow. Examine dilution, cash runway and commercial expansion.
Pharma & Biotech
What FDA’s latest ibezapolstat guidance means for Acurx and the IBZ-ASPIRE trial
FDA feedback may let Acurx use one Phase 3 ibezapolstat trial for C. difficile treatment and recurrence, but evidence and funding remain decisive.
Pharma & Biotech
Can Galmed’s dissolving Aramchol film turn a former liver drug into a Parkinson’s contender?
Galmed’s Aramchol film may simplify Parkinson’s dosing, but clinical proof and regulatory clearance remain ahead. See what matters next.
Medical Devices & Diagnostics
Novanta just made a $1.2bn surgical consumables bet. Can Riverpoint justify the price?
Novanta completes Riverpoint Medical acquisition, expanding surgical consumables and recurring revenue. See what integration and returns must deliver.
Pharma & Biotech
argenx Forte Biosciences acquisition: What the $2.2bn FB102 deal means for immunology
argenx is buying Forte Biosciences for $2.2bn to secure FB102. See why early vitiligo and celiac data make Phase 2 execution decisive.
Pharma & Biotech
Apnimed files for Nasdaq IPO as oral sleep apnea drug AD109 nears FDA review
Apnimed, Inc. has filed for an initial public offering in the United States as it prepares for a potentially decisive regulatory year for AD109, its once-nightly oral treatment for obstructive sleep apnea. The Cambridge, Massachusetts-based pharmaceutical company plans to list on the Nasdaq Global Market under the ticker APMD, although the number of shares, proposed
Pharma & Biotech
Compass Pathways has stronger COMP360 data, but can psilocybin treatment scale?
Find out how Compass Pathways’ COMP360 Phase 3 data could shape regulated psilocybin treatment for depression.
Pharma & Biotech
UroGen Pharma has FDA clearance for UGN-501, but can an oncolytic virus work in bladder cancer?
Find out how UroGen Pharma’s UGN-501 could test oncolytic virus therapy for recurrent non-muscle invasive bladder cancer.